- Home
- FNWB vs AVTX Comparison
FNWB vs AVTX Comparison
Compare FNWB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWB | AVTX |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 339.9M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FNWB | AVTX |
|---|---|---|
| Price | $8.90 | $15.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.50 | ★ $32.57 |
| AVG Volume (30 Days) | 27.4K | ★ 568.0K |
| Earning Date | 04-29-2026 | 04-20-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 36.00 | ★ 81.66 |
| EPS | ★ N/A | N/A |
| Revenue | $176,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $7.05 | $3.39 |
| 52 Week High | $10.98 | $20.72 |
Technical Indicators
Market Signals| Indicator | FNWB | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 45.48 |
| Support Level | $7.56 | $15.36 |
| Resistance Level | $9.00 | $16.40 |
| Average True Range (ATR) | 0.33 | 1.31 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 4.46 | 24.30 |
Price Performance
Historical ComparisonAbout FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).